EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
2023; Elsevier BV; Volume: 26; Issue: 12 Linguagem: Inglês
10.1016/j.jval.2023.09.807
ISSN1524-4733
AutoresCarlos E. Rodríguez‐Martínez, Johanna Gabriela Alvarez Ordoñez, Xavier Carbonell‐Estrany, John R. Fullarton, I. Keary, Barry Rodgers‐Gray, Ivonne D’Apremont, Sara Espinosa, Paulo A. Ribeiro, Renato T. Stein, Néstor Vain, Jean‐Éric Tarride, Bosco Paes,
Tópico(s)Public Health and Environmental Issues
Referência(s)